Loading
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Latest quote
$2.14
−$0.07 · -3.17%
After-hours
$2.10
−$0.04 · -1.87%
Oct 9, 4:16 PM ET
Regular session · ET · Market data may be delayed.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Day range
Current $2.14
52-week range
Current $2.14
Regular session · ET · Market data may be delayed.
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Day range
Current $2.14
52-week range
Current $2.14
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | — | — | 1.18M USD | 1.84M USD | 1.26M USD |
| Cost of goods sold | — | 352K USD | 889K USD | 1.54M USD | 1.3M USD |
| Gross profit | — | −352K USD | 287K USD | 299K USD | −46K USD |
| Research and development | 3.13M USD | 1.31M USD | 1.66M USD | 1.73M USD | 870K USD |
| Selling, general, and administrative | 4.77M USD | 2.75M USD | 6.88M USD | 8.67M USD | 4.72M USD |
| Operating expenses | 7.9M USD | 4.06M USD | 8.53M USD | 10.4M USD | 5.59M USD |
| Interest income | 23K USD | 6K USD | 1K USD | 2K USD | — |
| Interest expense | 146K USD | — | — | — | 1.82M USD |
| Depreciation and amortization | 5K USD | 352K USD | 182K USD | 174K USD | 24K USD |
| Operating income | −7.9M USD | −4.42M USD | −8.25M USD | −10.1M USD | −5.63M USD |
| Net income | −8.88M USD | −5.66M USD | −8.24M USD | −10.1M USD | −8.49M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
